| Literature DB >> 28608823 |
Victor Forman1,2, Roberta Callari3, Christophe Folly4, Harald Heider5, Björn Hamberger6.
Abstract
The development of medical applications exploiting the broad bioactivities of the diterpene therapeutic triptolide from Tripterygium wilfordii is limited by low extraction yields from the native plant. Furthermore, the extraordinarily high structural complexity prevents an economically attractive enantioselective total synthesis. An alternative production route of triptolide through engineered Saccharomyces cerevisiae (yeast) could provide a sustainable source of triptolide. A potential intermediate in the unknown biosynthetic route to triptolide is the diterpene dehydroabietic acid. Here, we report a biosynthetic route to dehydroabietic acid by transient expression of enzymes from T. wilfordii and Sitka spruce (Picea sitchensis) in Nicotiana benthamiana. The combination of diterpene synthases TwTPS9, TwTPS27, and cytochromes P450 PsCYP720B4 yielded dehydroabietic acid and a novel analog, tentatively identified as 'miltiradienic acid'. This biosynthetic pathway was reassembled in a yeast strain engineered for increased yields of the pathway intermediates, the diterpene olefins miltiradiene and dehydroabietadiene. Introduction in that strain of PsCYP720B4 in combination with two alternative NADPH-dependent cytochrome P450 reductases resulted in scalable in vivo production of dehydroabietic acid and its analog from glucose. Approaching future elucidation of the remaining biosynthetic steps to triptolide, our findings may provide an independent platform for testing of additional recombinant candidate genes, and ultimately pave the way to biotechnological production of the high value diterpenoid therapeutic.Entities:
Keywords: Nicotiana benthamiana; Saccharomyces cerevisiae; Tripterygium wilfordii; dehydroabietadiene; dehydroabietic acid; medicinal diterpenes; miltiradiene; miltiradienic acid; triptolide
Mesh:
Substances:
Year: 2017 PMID: 28608823 PMCID: PMC6152743 DOI: 10.3390/molecules22060981
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Proposed pathway to triptolide with a key intermediate, dehydroabietic acid. Dehydroabietic acid (3) is produced from dehydroabietadiene (2), a product of a pair of diTPS via copalyl diphosphate (normal-CPP) in normal, or (+) stereochemical configuration, to miltiradiene (1) that can undergo spontaneous aromatization into 2. 2 is functionalized into 3 by CYP720B4, cytochrome P450. 3 possibly undergoes a carboxylic rearrangement and dehydrogenation to triptobenzene D as a subsequent step. The remaining steps in T. wilfordii towards triptolide could be catalyzed by other P450s. All diterpenoid intermediates in the proposed pathway have been reported in T. wilfordii, with exception of the unstable intermediate that undergoes spontaneous lactonization into triptophenolide.
Figure 2Identification of a dehydroabietic acid (3) pathway by transient expression in tobacco. (A) Transiently expressed genes with confirmed and putative diterpene products detected after derivatization; MW, molecular weight, corresponding to m/z for 4d and 3d; (B) Total ion chromatograms (TIC) of control plants without diTPS, plants expressing TwTPS9 and TwTPS27 (MILT (-)) and the addition of PsCYP720B4; (C) Extracted ion chromatograms (EIC) of m/z 197, characteristic for both diterpene products, showing novel peaks 3d and 4d when PsCYP720B4 was expressed in combination with diTPSs; (D) MS spectra of 3d corresponding to derivatized methyl-ester of 3; (E) MS spectra of 4d corresponding to putative methyl-ester of miltiradienic acid (4).
Figure 3Production of diterpene olefins 1 and 2 in engineered yeast. (A) Pathway leading to dehydroabietadiene from GGPPS. Putative hydrolyzed products of GGPP into GGOH (5) and copalyl-diphosphate (CPP) into copalol (6) were detected (Figure S1); (B) Total ion chromatograms (TIC) of control strain without diTPSs and the strain YS2 expressing codon optimized truncated TwTPS9 and TwTPS27; (C) Normalized peak areas to cell density of 1 and 2 for all yeast strains.
Figure 4Production of the target and putative triptolide intermediate 3 and its analog 4 in yeast. (A) Extracted ion chromatograms (EIC) with m/z 197 of control strains expressing CPRs and diTPS, and strains additionally expressing PsCYP720B4; (B) Comparison of MS spectra between yeast product 4d (above) and reported spectrum of methyl-8,12-abietadien-18-oate (below) reported by [31]; (C) MS spectrum of yeast product 3d; (D) MS spectrum of authentic methyl-dehydroabietate (3d) matching yeast product 3d.
Yeast strains used and generated in this study.
| Name | Genotype |
|---|---|
| EYS2010 | |
| YS1 | [CEN/ARS/pPGK1-CO_ |
| YS2 | [CEN/ARS/pPGK1-CO_Δ46 |
| YS3 | [CEN/ARS/pPGK1-WT_ |
| YS4 | [CEN/ARS/pPGK1-WT_Δ46 |
| YS2-1 | [CEN/ARS/pPGK1-CO_Δ46 |
| YS2-2 | [CEN/ARS/pPGK1-CO_Δ46 |
| ATR1 (−) | [CEN/ARS/pPGK1-CO_Δ46 |
| [CEN/ARS/pPGK1-CO_Δ46 |